Shots:
- The US FDA has approved the company’s Vafseo (vadadustat) tablets as a treatment of anemia associated with chronic kidney disease (CKD) in adults on dialysis for at least 3mos. The company, in collaboration with CSL Vifor, will commercialize Vafseo across the US
- The approval was based on the safety and efficacy results from INNO2VATE trial and an evaluation of safety outcomes after marketing in Japan. The results were published in the New England Journal of Medicine
- Vafseo (oral, QD) is a HIF-PH inhibitor that triggers the body’s response to hypoxia by promoting the production of erythropoietin to address anemia
Ref: PRNewswire | Image: Akebia | Press Release
Related News:- Merck’s Winrevair (sotatercept-csrk) Receives the US FDA’s Approval for the Treatment of Pulmonary Arterial Hypertension (PAH)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
